Date: 2015-03-02
Type of information: Nomination
Compound:
Company: Incyte (USA - DE)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 2, 2015, Incyte Corporation announced that Steven H. Stein , MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte\'s extensive oncology portfolio. He will join the executive management team of Incyte , and report to Richard S. Levy , MD, Executive Vice President and Chief Drug Development Officer. Dr. Stein\'s primary responsibility at Novartis was leading Novartis Oncology\'s North American medical/scientific activities, including the planning, resource allocation and execution of registration and non-registration studies. He was also responsible for the Medical Sciences & Health Outcomes function, which included the Scientific Communications , Medical Information and Health Economics and Outcomes Research groups. Dr. Stein previously worked at GSK as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his MD from the University of Witwatersrand in Johannesburg, South Africa . He has authored more than 100 scientific papers and presentations and is also an active member of several professional and scientific societies and academic committees.
Financial terms:
Latest news:
